The Use of Cranial Electrotherapy Stimulation in the Treatment of Multiple Sclerosis [Abstract]
Smith, Ray B. The Original
Internist, 9(3):25-28, September, 2002.
When the author worked as
vice president of research at Electromedical Products International, Inc. he
received two testimonial letters giving glowing reports of the effectiveness of
Alpha-Stim CES in reducing or alleviating several of the major symptoms of
multiple sclerosis (MS). Until then no one had considered the possibility of
CES as a treatment for MS.
The author then checked
through the EPI database of thousands of warranty cards and found 12 cards that
had been sent in by patients who had been prescribed an Alpha-Stim for their
MS. They claimed an average improvement of 46.57% (range of 0-99%) in their
symptoms. Ten of the 12 were females, ages ranged from 21-52 year old (average
age was 39), and they used CES 1 - 8 weeks (average 4.4 weeks, or one
month). Based on this preliminary evidence a pilot study was conducted.
After giving informed consent, five patients (three females) used the
Alpha-Stim for one hour a day for one month, at 0.5 Hz and a comfortable level
of current between 100 and 300 µA. MS diagnoses ranged from 10 - 38 years
(average of 21), ages ranged from 53 - 68 years old (average age was 60).
Improvement was noted in seven
of the ten symptoms measured. Self rated spasticity improved 54%, vision
improved 50%, sensory (ability to feel) improved 45%, fatigue improved 40%,
pain improved 29% and hand function improved 22% in the left hand and 12% in
the right hand. Bladder, cognitive and mobility/gait function was not rated as
significantly improved by these patients.
The author concluded that
while this is only a pilot study, the results were consistent with letters and
warranty cards received and so this study is probably a fairly accurate
assessment of what a physician could expect when prescribing a CES device for
use by MS patients.
 Use of CES in Treatment of Multiple Sclerosis 341.29 Kb
|
For Practitioners 
